- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00212355
Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan.
April 14, 2019 updated by: Nobelpharma
Phase3, Open-Label, Clinical Trial of Zinc Acetate for Treatment of Wilson's Disease in Japan.
The purpose of this long-term study is to determine whether Zinc Acetate is effective and safe in the treatment of Wilson's disease among Japanese.
Study Overview
Detailed Description
Wilson disease is an autosomal recessive disorder with copper metabolism.
In Japan, the standard treatment is the use of copper chelating agents, such as D-penicillamine and trientine.
In this study, we investigate efficacy on zinc acetate in Japanese patients with Wilson disease.
Study Type
Interventional
Enrollment (Actual)
37
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year and older (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Wilson's disease(adult, infant, pregnant woman)
Exclusion Criteria:
- Acute hepatitis
- Malignant tumor
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: NPC-02
zinc acetate
|
zinc acetate
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Efficacy
Time Frame: During study period (up to 96W )
|
Number of patients who have at least one adverse events.
ALT Change
|
During study period (up to 96W )
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Koudou Ishii, M.D., National MINAMIYOKOHAMA Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2005
Primary Completion (ACTUAL)
April 1, 2008
Study Completion (ACTUAL)
January 1, 2009
Study Registration Dates
First Submitted
September 13, 2005
First Submitted That Met QC Criteria
September 13, 2005
First Posted (ESTIMATE)
September 21, 2005
Study Record Updates
Last Update Posted (ACTUAL)
April 24, 2019
Last Update Submitted That Met QC Criteria
April 14, 2019
Last Verified
April 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Liver Diseases
- Genetic Diseases, Inborn
- Basal Ganglia Diseases
- Movement Disorders
- Neurodegenerative Diseases
- Metabolism, Inborn Errors
- Heredodegenerative Disorders, Nervous System
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Metal Metabolism, Inborn Errors
- Hepatolenticular Degeneration
Other Study ID Numbers
- NPC-02-2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Wilson's Disease
-
Vivet Therapeutics SASRecruitingWilson's DiseaseUnited States, Denmark, Germany, United Kingdom
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Univar BVAptiv SolutionsCompleted
-
Fondation Ophtalmologique Adolphe de RothschildRecruiting
-
Fondation Ophtalmologique Adolphe de RothschildRecruiting
-
OrphalanErgomedRecruitingWilson's DiseaseSpain, United Kingdom, Belgium, Germany, Poland, France, Saudi Arabia
-
OrphalanCompletedWilson's DiseaseUnited Kingdom
-
University College, LondonUnknown
Clinical Trials on NPC-02
-
NobelpharmaCompleted
-
NobelpharmaCompleted
-
NobelpharmaCompletedCytomegalovirus DiseaseUnited States, Japan
-
NobelpharmaCompleted
-
NobelpharmaTerminatedNeuropathic Pain in CancerJapan
-
Cedars-Sinai Medical CenterCalifornia Institute for Regenerative Medicine (CIRM)Recruiting
-
Tohoku UniversityCompletedHereditary Inclusion Body Myopathy | Nonaka MyopathyJapan
-
NobelpharmaCompletedGNE Myopathy | Nonaka Disease | Distal Myopathy With Rimmed Vacuoles (DMRV) | Hereditary Inclusion Body Myopathy (hIBM)Japan
-
Sun Yat-sen UniversityUnknownNasopharyngeal CarcinomaChina